| Name | Title | Contact Details |
|---|
Intact Public Entities is a leader in providing specialized insurance programs, including risk management and claims services to municipal, public administration and community service organizations across Canada. Proven industry knowledge, gained through over nine decades of partnering with insurance companies and independent brokers, gives Intact Public Entities the ability to effectively manage the necessary risk, advisory and claims services for both standard and complex issues. Our history dates back to 1927 with our first municipal client - the Village of Ayr, Ontario. From then, other municipalities came calling and the company established the strong foundation and sterling reputation that continues today. Interestingly, our product offering was expanded beyond municipal business based on reputation. Other municipal-related organizations started to be asked to be placed with us because of our knowledge in the specialty insurance space. The trend continued and it became common for the municipality, hospital, Childrens Aid Society and conservation authority to all be placed wtih Intact Public Entities. Intact Public Entities is a Managing General Agent (MGA) with the authority to write and service business on behalf of strategic partners who share our commitment and dedication to protecting specialized organizations. Because our partners are long-term participants on our program, they understand the nature of fluctuating market conditions and complex claims and are prepared to stay the course. Intact Public Entities is a wholly owned subsidiary of Intact Financial Corporation.
Mymcpl is a Missouri-based nonprofit organization that provides notary, remote printing, and passport services for individuals.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The WSAVA represents more than 200,000 veterinarians worldwide through its 110 member associations and works to enhance standards of clinical care for companion animals. Its core activities include the development of WSAVA Global Guidelines in key areas of companion animal veterinary practice and lobbying on important issues affecting companion animal care worldwide.